Tim Heise
PROFILE Institute for Metabolic Research GmbH, NORTH RHINE-WESTPHALIA, Germany
- This delegate is presenting an abstract at this event.
Dr Heise is Lead Scientist and Chairman of the Board of Directors of the private research institute Profil in Neuss, Germany. Founded in 1999 by Dr Heise and Dr Lutz Heinemann, Profil quickly became known as the premier source of solutions to the challenging early phase studies of experimental diabetes treatments; in particular pharmacodynamic/pharmacokinetic assess-ments performed with the glucose clamp technique.
Dr Heise has led numerous early and later phase studies concerning insulin resistance, hypertension, obesity, antidiabetic drugs and insulin administration forms, as well as pharmacokinetic and pharmacodynamic properties of novel insulin preparations. In addition, his study team at Profil has gained outstanding reputation for the evaluation of medical devices, in particular non-invasive and minimally invasive glucose sensors.
Before establishing Profil, Dr Heise worked for more than 7 years at the clinic for nutrition and metabolic diseases at the Heinrich-Heine-University Düsseldorf. During this time he was responsible for the diabetes outpatient clinic (including patients suffering from microvascular complications and the diabetic foot syndrome) and the obesity outpatient clinic. He also was the responsible physician for patients participating in structured teaching and treatment programs for type 1 and type 2 diabetes and hypertension.
In addition to his clinical work Dr Heise has published more than 160 scientific papers and reviews on the characteristics of novel insulins, but also on the topic of insulin sensitivity, treatment of type 2 diabetes, hypertension and diabetic nephropathy.
Dr Heise is reviewer for several scientific journals and member of the Editorial Board of Diabetes, Obesity and Metabolism.
Presentations this author is a contributor to:
Earlier onset of exposure and greater early pharmacokinetic and pharmacodynamic effects for faster-acting insulin aspart vs. insulin aspart using continuous subcutaneous insulin infusion (#162)
9:45 AM
Tim Heise
ADS Clinical Orals - Type 1 Diabetes
Faster-acting insulin aspart demonstrates higher early insulin exposure and greater early glucose-lowering effect vs. insulin aspart across a clinically relevant dose range (#165)
10:30 AM
Tim Heise
ADS Clinical Orals - Type 1 Diabetes
How fast is fast enough? New insulins for improved prandial glucose control (#110)
1:15 PM
Tim Heise
ADS Meet the Expert